The approval of tepotinib in Japan in 2020 was the first regulatory approval globally for an oral MET inhibitor for treatment of advanced NSCLC harboring METex14 skipping alterations, and was followed by approvals in multiple other countries/regions (55). Here, MET is linked to non-small cell lung carcinoma.